Aurinia Pharmaceuticals (AUPH) Current Assets (2016 - 2026)

Aurinia Pharmaceuticals' Current Assets history runs 11 years deep, the most recent figure standing at $480.2 million for Q1 2026.

• Quarterly Current Assets rose 18.36% year-over-year to $480.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $480.2 million (up 18.36% YoY) and the FY2025 annual result came in at $492.0 million, up 10.16% from the prior year.
• Current Assets was $480.2 million for Q1 2026 at Aurinia Pharmaceuticals, down from $492.0 million in the prior quarter.
• Across five years, Current Assets topped out at $492.0 million in Q4 2025 and bottomed at $398.2 million in Q1 2024.
• A 5-year average of $437.9 million and a median of $438.7 million in 2025 frame the typical range for Current Assets.
• Peak annual rise in Current Assets reached 39.63% in 2022, while the deepest fall reached 13.79% in 2022.
• Aurinia Pharmaceuticals' Current Assets stood at $442.5 million in 2022, then declined by 4.01% to $424.8 million in 2023, then grew by 5.13% to $446.6 million in 2024, then increased by 10.16% to $492.0 million in 2025, then fell by 2.38% to $480.2 million in 2026.
• Business Quant data shows AUPH's Current Assets at $480.2 million in Q1 2026, $492.0 million in Q4 2025, and $438.7 million in Q3 2025.